Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: Recommendations of HDL Forum

被引：22

作者：

Ascaso J.F. ^{[1
]}

Fernández-Cruz A. ^{[2
]}

González Santos P. ^{[3
]}

Hernández Mijares A. ^{[4
]}

Mangas Rojas A. ^{[5
]}

Millán J. ^{[6
]}

Pallardo L.F. ^{[7
]}

Pedro-Botet J. ^{[8
]}

Pérez-Jiménez F. ^{[9
]}

Pía G. ^{[10
]}

Pintó X. ^{[11
]}

Plaza I. ^{[12
]}

Rubiés-Prat J. ^{[13
]}

机构：

[1] Endocrinology Service, Clinic University Hospital, University of Valencia, Valencia

[2] Cardiovascular Institute, Hospital Clinico San Carlos, Complutense University of Madrid, Madrid

[3] Department of Internal Medicine, Univ. Hospital Virgen de la Victoria, Málaga

[4] Endocrinology Service, Peset University Hospital, University of Valencia, Valencia

[5] Internal Medicine Service, Puerta del Mar University Hospital, Cádiz

[6] Internal Medicine Service, Gen. Univ. Hospital Gregorio Maranon, E-28007 Madrid

[7] Endocrinology and Nutrition Service, La Paz University Hospital, Madrid

[8] Department of Internal Medicine, Hospital del Mar, Universidad Autonoma de Barcelona, Barcelona

[9] Lipid and Atherosclerosis Unit, Internal Medicine Service, Reina Sofia University Hospital, Cordoba

[10] Internal Medicine Service, Hosp. Arq. Marcide-Prof. N. Santos, Ferrol

[11] Lipid and Atherosclerosis Unit, Internal Medicine Service, Bellvitge University Hospital, Barcelona

[12] Cardiology Service, La Paz University Hospital, Madrid

[13] Department of Medicine, Universidad Autonoma de Barcelona, Barcelona

来源：

American Journal of Cardiovascular Drugs | 2004年 / 4卷 / 5期

关键词：

Fenofibrate; Gemfibrozil; Fibric Acid Derivative; Cardiovasc Drug; Ischemic Heart Disease Risk;

D O I：

10.2165/00129784-200404050-00003

中图分类号：

学科分类号：

摘要：

In the approach to lipid-related risk factors for cardiovascular diseases, serum high density lipoprotein-cholesterol (HDL-C) levels bear a particular significance as this lipoprotein is considered to be an antiatherogenic factor mainly, but not only, because of its influence and impact on reverse cholesterol transport. Hence the need and requirement to consider serum HDL-C levels for both primary and secondary prevention of cardiovascular disease. A particularly important aspect is the association of the 'low HDL syndrome' with the metabolic syndrome. These factors force us to consider serum HDL-C level as a therapeutic target by itself, or even in association with low density lipoprotein-cholesterol (LDL-C) levels when the latter are increased. This review stresses the aspects connecting serum HDL-C levels and cardiovascular risk, and looks at the populations that should be considered amenable to therapeutic management because of low serum HDL-C levels. We review therapeutic strategies, both pharmacological and nonpharmacological. The aim of this review is to present therapeutic management recommendations for correcting the proportion of cardiovascular risk that is attributable to changes in HDL-C. Serum HDL-C levels of >40 mg/dL must be a therapeutic target in primary and secondary prevention. This goal is particularly important in patients with low serum HDL-C levels and ischemic heart disease (IHD) or its equivalents, even if the therapeutic target for serum LDL-C levels (< 100 mg/ dL) has been achieved. The first choice for this clinical condition is fibric acid derivates. The same therapeutic option should be considered in patients without IHD with low serum HDL-C levels and high cardiovascular risk (>20%), hypertriglyceridemia, type 2 diabetes mellitus, or metabolic syndrome. © 2004 Adis Data Information BV. All rights reserved.

引用

页码：299 / 314

页数：15

共 96 条

[11]

Salonen J.T., Salonen R., Seppanen K., Et al., HDL, HDL2 and HDL3 subfractions and the risk of acute myocardial infarction: A prospective population study in eastern Finnish men, Circulation, 84, pp. 129-139, (1991)

[12]

Assmann G., Schulte H., von Eckardstein A., Et al., High density lipoprotein cholesterol as a predictor of coronary heart disease risk: The PROCAM experience and pathophysiological implications for reverse cholesterol transport, Atherosclerosis, 124, SUPPL., (1996)

[13]

Durrington P., Hyperlipidaemia: Diagnosis and Management, (1995)

[14]

Corti M.C., Guralnik J.M., Salive M.E., Et al., HDL cholesterol predicts coronary heart disease mortality in older persons, JAMA, 274, pp. 539-544, (1995)

[15]

Lu W., Resnick H.E., Jablonski K.A., Et al., Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The Strong Heart Study, Diabetes Care, 26, pp. 16-23, (2003)

[16]

Gordon D.J., Probstfield J.L., Garrison J.R., Et al., High density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies, Circulation, 79, pp. 8-15, (1989)

[17]

Plaza I., Mariscal R.P., Muoz M.T., Et al., Estudio de Fuenlabrada: Asociación entre los niveles de lípidos y lipoproteínas en niños y adolescentes con la prevalencia de cardiopatía isquémica en sus familiares, Rev. Esp. Cardiol., 43, pp. 212-218, (1990)

[18]

Control de la colesterolemia en España 2000: Un instrumento para la prevención cardiovascular, (2000)

[19]

Castelli W.P., Garrison R.J., Wilson W., Et al., Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham study, JAMA, 256, pp. 2835-2838, (1986)

[20]

Pekkanen J., Linn S., Heiss G., Et al., Ten year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease, N. Engl. J. Med., 322, pp. 1700-1707, (1990)

← 1 2 3 4 5 6 7 8 9 10 →